Next Article in Journal
Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
Next Article in Special Issue
Molecular Imaging of the Dopamine Transporter
Previous Article in Journal
Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort
Previous Article in Special Issue
Microbiome, Parkinson’s Disease and Molecular Mimicry
Open AccessReview

GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches

1
The Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders, NYU Langone Health, New York, NY 10017, USA
2
Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy
3
Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
Cells 2019, 8(4), 364; https://doi.org/10.3390/cells8040364
Received: 21 March 2019 / Revised: 13 April 2019 / Accepted: 16 April 2019 / Published: 19 April 2019
(This article belongs to the Special Issue The Molecular and Cellular Basis for Parkinson's Disease)
Parkinson’s disease (PD) is the second most common degenerative disorder. Although the disease was described more than 200 years ago, its pathogenetic mechanisms have not yet been fully described. In recent years, the discovery of the association between mutations of the GBA gene (encoding for the lysosomal enzyme glucocerebrosidase) and PD facilitated a better understating of this disorder. GBA mutations are the most common genetic risk factor of the disease. However, mutations of this gene can be found in different phenotypes, such as Gaucher’s disease (GD), PD, dementia with Lewy bodies (DLB) and rapid eye movements (REM) sleep behavior disorders (RBDs). Understanding the pathogenic role of this mutation and its different manifestations is crucial for geneticists and scientists to guide their research and to select proper cohorts of patients. Moreover, knowing the implications of the GBA mutation in the context of PD and the other associated phenotypes is also important for clinicians to properly counsel their patients and to implement their care. With the present review we aim to describe the genetic, clinical, and therapeutic features related to the mutation of the GBA gene. View Full-Text
Keywords: glucocerebrosidase; Parkinson’s disease; Gaucher’s disease; Lewy Body Dementia; REM sleep behavior disorders glucocerebrosidase; Parkinson’s disease; Gaucher’s disease; Lewy Body Dementia; REM sleep behavior disorders
Show Figures

Figure 1

MDPI and ACS Style

Riboldi, G.M.; Di Fonzo, A.B. GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 2019, 8, 364.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop